Seroconversion of a city: Longitudinal monitoring of SARS-CoV-2 seroprevalence in New York City
Authors:
- Daniel StadlbauerDSDaniel Stadlbauer
- Jessica TanJTJessica Tan
- Kaijun JiangKJKaijun Jiang
- Matthew M. HernandezMHMatthew M. Hernandez
- Shelcie FabreSFShelcie Fabre
- Fatima AmanatFAFatima Amanat
- Catherine TeoCTCatherine Teo
- Guha Asthagiri ArunkumarGAGuha Asthagiri Arunkumar
- Meagan McMahonMMMeagan McMahon
- Jeffrey JhangJJJeffrey Jhang
- Michael D. NowakMNMichael D. Nowak
- Viviana SimonVSViviana Simon
Preprint
Abstract
By conducting a retrospective, cross-sectional analysis of SARS-CoV-2 seroprevalence in a ‘sentinel group’ (enriched for SARS-CoV-2 infections) and a ‘screening group’ (representative of the general population) using >5,000 plasma samples from patients at Mount Sinai Hospital in New York City (NYC), we identified seropositive samples as early as in the week ending February 23, 2020. A stark increase in seropositivity in the sentinel group started the week ending March 22 and in the screening group in the week ending March 29. By the week ending April 19, the seroprevalence in the screening group reached 19.3%, which is well below the estimated 67% needed to achieve community immunity to SARS-CoV-2. These data potentially suggest an earlier than previously documented introduction of SARS-CoV-2 into the NYC metropolitan area. One Sentence Summary: Seroprevalence of SARS-CoV-2 in cross-sectional samples from New York City rose from 0% to 19.3% from early February to mid-April.Keywords
All Related Versions
- Published version: Nature, 590 (7844), 146.
This publication has 12 references indexed in Scilit:
- Introductions and early spread of SARS-CoV-2 in the New York City areaScience, 2020
- Serology assays to manage COVID-19Science, 2020
- Cumulative incidence and diagnosis of SARS-CoV-2 infection in New YorkmedRxiv, 2020
- Humoral immune response and prolonged PCR positivity in a cohort of 1343 SARS-CoV 2 patients in the New York City regionmedRxiv, 2020
- Herd Immunity: Understanding COVID-19Immunity, 2020
- SARS‐CoV‐2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test SetupCurrent Protocols in Microbiology, 2020
- A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoVbioRxiv, 2020
- Case Fatality Risk of Influenza A (H1N1pdm09)Epidemiology, 2013
- Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape MutantsPLOS Medicine, 2006
- Interval Estimation for a Binomial ProportionStatistical Science, 2001